Tower Research Capital LLC TRC Raises Position in Sight Sciences, Inc. (NASDAQ:SGHT)

Tower Research Capital LLC TRC raised its holdings in shares of Sight Sciences, Inc. (NASDAQ:SGHT) by 180.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 12,076 shares of the company’s stock after buying an additional 7,764 shares during the quarter. Tower Research Capital LLC TRC’s holdings in Sight Sciences were worth $62,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in SGHT. Lazard Asset Management LLC purchased a new position in Sight Sciences in the fourth quarter worth $54,000. FMR LLC boosted its holdings in shares of Sight Sciences by 484.6% in the 2nd quarter. FMR LLC now owns 4,864 shares of the company’s stock worth $44,000 after purchasing an additional 4,032 shares in the last quarter. US Bancorp DE bought a new position in shares of Sight Sciences during the 4th quarter valued at about $27,000. Cubist Systematic Strategies LLC purchased a new position in shares of Sight Sciences during the 3rd quarter valued at about $37,000. Finally, Barclays PLC lifted its position in Sight Sciences by 540.7% in the 4th quarter. Barclays PLC now owns 5,850 shares of the company’s stock worth $72,000 after buying an additional 4,937 shares during the last quarter. 55.51% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the completion of the transaction, the chief financial officer now owns 426,248 shares of the company’s stock, valued at $2,165,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $51,424.84. Following the completion of the transaction, the chief financial officer now owns 426,248 shares of the company’s stock, valued at $2,165,339.84. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, COO Sam Boong Park sold 5,443 shares of the firm’s stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $5.16, for a total value of $28,085.88. Following the transaction, the chief operating officer now directly owns 100,735 shares of the company’s stock, valued at approximately $519,792.60. The disclosure for this sale can be found here. Insiders sold 63,441 shares of company stock valued at $324,625 over the last quarter. 27.10% of the stock is owned by company insiders.

Sight Sciences Trading Down 5.4 %

Shares of SGHT stock traded down $0.30 during mid-day trading on Tuesday, reaching $5.23. The stock had a trading volume of 131,683 shares, compared to its average volume of 228,507. The firm has a market capitalization of $259.15 million, a PE ratio of -4.59 and a beta of 2.83. The stock’s 50-day moving average price is $4.80 and its two-hundred day moving average price is $4.04. The company has a current ratio of 13.29, a quick ratio of 12.65 and a debt-to-equity ratio of 0.26. Sight Sciences, Inc. has a 52-week low of $1.04 and a 52-week high of $11.20.

Sight Sciences (NASDAQ:SGHT) last announced its quarterly earnings results on Thursday, March 7th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.13. Sight Sciences had a negative return on equity of 41.94% and a negative net margin of 68.53%. The company had revenue of $18.75 million during the quarter, compared to analyst estimates of $18.70 million. During the same quarter last year, the firm posted ($0.35) earnings per share. Equities analysts expect that Sight Sciences, Inc. will post -1.04 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Needham & Company LLC reissued a “hold” rating on shares of Sight Sciences in a research note on Wednesday, April 10th. One research analyst has rated the stock with a sell rating, five have given a hold rating and one has given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus price target of $4.60.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.